The impact of the 21-gene Recurrence Score® assay upon physician treatment recommendations in the neoadjuvant setting in lymph node-negative breast cancer patients in a multicenter prospective study in Quebec

被引：0
|
作者：
Yordanova, Mariya
Sideris, Lucas
Dube, Pierre
Boileau, Jean-Francois
Lemieux, Julie
Mihalcioiu, Catalin
Levesque, Sylvie
Guertin, Marie-Claude
Patocskai, Erica
Younan, Rami
Robidoux, Andre
Hassan, Saima
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-01-39
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-01-39
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A prospective multicenter study evaluating the impact of the 21-Gene Breast Recurrence Score® upon physician treatment decision and cost in lymph node-positive breast cancer patients in Quebec
    Hassan, Saima
    Younan, Rami
    Patocskai, Erica
    Provencher, Louise
    Poirier, Brigitte
    Sideris, Lucas
    Dube, Pierre
    Boileau, Jean-Francois
    Mihalcioiu, Catalin
    Robidoux, Andre
    CANCER RESEARCH, 2021, 81 (04)
  • [2] Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec
    Hassan, Saima
    Younan, Rami
    Patocskai, Erica
    Provencher, Louise
    Poirier, Brigitte
    Sideris, Luca
    Dube, Pierre
    Mihalcioiu, Catalin
    Chabot-Blanchet, Malorie
    Guertin, Marie-Claude
    Boileau, Jean-Francois
    Robidoux, Andre
    ONCOLOGIST, 2022, 27 (10): : 822 - 831
  • [3] The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?
    Jerzak, Katarzyna J.
    Pritchard, Kathleen I.
    EUROPEAN JOURNAL OF CANCER, 2016, 68 : 173 - 175
  • [4] 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer
    Gulisa Turashvili
    Joanne F. Chou
    Edi Brogi
    Monica Morrow
    Maura Dickler
    Larry Norton
    Clifford Hudis
    Hannah Y. Wen
    Breast Cancer Research and Treatment, 2017, 166 : 69 - 76
  • [5] 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer
    Turashvili, Gulisa
    Chou, Joanne F.
    Brogi, Edi
    Morrow, Monica
    Dickler, Maura
    Norton, Larry
    Hudis, Clifford
    Wen, Hannah Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 69 - 76
  • [6] Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
    Nathan W. D. Lamond
    Chris Skedgel
    Daniel Rayson
    Lynn Lethbridge
    Tallal Younis
    Breast Cancer Research and Treatment, 2012, 133 : 1115 - 1123
  • [7] Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer
    Lamond, Nathan W. D.
    Skedgel, Chris
    Rayson, Daniel
    Lethbridge, Lynn
    Younis, Tallal
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 1115 - 1123
  • [8] Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage
    Yang Yu-qing
    Wang Lei
    Huang Mei-ling
    Xiao Jing-jing
    Wei Mei-chen
    Wu Jiang
    Hao Jun-sheng
    Ling Rui
    Li Nan-lin
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2019, 108 : 150 - 155
  • [9] Predictive value of 21-gene recurrence score assay in non-estrogen receptor-positive and lymph node-negative breast cancer
    Lu, Kai
    Li, Hui
    Wu, Zhaoshu
    Liu, Dong
    Ye, Hongling
    Xu, Liang
    Liu, Yanwen
    JOURNAL OF BUON, 2018, 23 (05): : 1297 - 1301
  • [10] Metabolic syndrome and recurrence within the 21-gene recurrence score assay risk categories in lymph node negative breast cancer
    Lakhani, A.
    Guo, R.
    Duan, X.
    Ersahin, C.
    Gaynor, E. R.
    Godellas, C.
    Kay, C.
    Lo, S. S.
    Mai, H.
    Perez, C.
    Albain, K.
    Robinson, P.
    CANCER RESEARCH, 2012, 72
12345